SCHEMBL185396

SCHEMBL185396

Cc1ccccc1N(c1ccc(N(c2ccccc2)c2ccc(-c3ccc(N(c4ccccc4)c4ccc(N(c5ccccc5C)c5ccccc5C)cc4)cc3)cc2)cc1)c1ccccc1C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.43
ALDH1A1 P00352 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
MAPT P10636 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
APP P05067 2/20 0.38
MEN1 O00255 1/20 0.37
CRHBP P24387 1/20 0.37
KMT2A Q03164 1/20 0.37
ATM Q13315 1/20 0.37
CRHR2 Q13324 1/20 0.37
TLR9 Q9NR96 1/20 0.37
TSHR P16473 1/20 0.35
ACHE P22303 1/20 0.35
HDAC6 Q9UBN7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1153906 1.00 CYP3A4 (0.43) CYP3A4ALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL31390117 0.96 CYP3A4 (0.43) CYP3A4ALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL19102572 0.96 CYP3A4 (0.43) CYP3A4ALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL16324036 0.96 CYP3A4 (0.43) CYP3A4ALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL73930 0.94 CYP3A4 (0.40) CYP3A4ALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL15306327 0.94 ALDH1A1 (0.38) CYP3A4ALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL13929897 0.94 CYP3A4 (0.40) CYP3A4ALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL7154196 0.94 ACHE (0.39) CYP3A4ALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL13929896 0.94 ACHE (0.39) CYP3A4ALDH1A1L3MBTL1KDM4ECYP1A2
SCHEMBL2887338 0.92 ALDH1A1 (0.39) CYP3A4ALDH1A1L3MBTL1KDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2478576-B9 ORGANIC ELECTRONIC DEVICE AND DOPANT FOR DOPING AN ORGANIC SEMICONDUCTING MATRIX MATERIAL OSRAM OLED GMBH (DE) 2017-09-06 EP claimed
EP-2478576-B1 ORGANIC ELECTRONIC DEVICE AND DOPANT FOR DOPING AN ORGANIC SEMICONDUCTING MATRIX MATERIAL OSRAM OLED GMBH (DE) 2017-05-31 EP claimed
US-20140361257-A1 ORGANIC LIGHT EMITTING DIODE DISPLAY SAMSUNG DISPLAY CO., LTD. (KR) 2014-12-11 US claimed
US-8610113-B2 Material for a hole transport layer with p-dopant SIEMENS AKTIENGESELLSCHAFT (DE) 2013-12-17 US claimed
US-20120146006-A1 MATERIAL FOR A HOLE TRANSPORT LAYER WITH P-DOPANT NOVALED GMBH (DE) 2012-06-14 US claimed
US-12538704-B2 4H-imidazo[1,2-a]imidazoles for electronic applications UDC IRELAND LIMITED (IE) 2026-01-27 US disclosed
US-20250185502-A1 ORGANIC OPTOELECTRONIC COMPONENT, ORGANIC FUNCTIONAL LAYER, AND METHOD FOR PRODUCING AN OPTOELECTRONIC COMPONENT OSRAM OLED GMBH (DE) 2025-06-05 US disclosed
WO-2025100171-A1 CHARGE-TRANSPORTING VARNISH AND CHARGE-TRANSPORTING VARNISH FOR QUANTUM DOT ELECTROLUMINESCENT ELEMENT 日産化学株式会社 2025-05-15 WO disclosed
US-12302747-B2 Optoelectronic component, organic functional layer, and method for producing an optoelectronic component OSRAM OLED GMBH (DE) 2025-05-13 US disclosed
WO-2025084125-A1 CHARGE-TRANSPORTING INK COMPOSITION AND INK COMPOSITION FOR UPPER LAYER FILM OF QUANTUM DOT LAYER 日産化学株式会社 2025-04-24 WO disclosed
CN-107814821-B Metal complexes with dibenzo [ F, H ] quinoxalines UDC 爱尔兰有限责任公司 2025-03-07 CN disclosed
WO-2025041715-A1 CHARGE-TRANSPORTING INK COMPOSITION AND SURFACE-TREATED METAL OXIDE NANOPARTICLE SOL 日産化学株式会社 2025-02-27 WO disclosed
US-20110309346-A1 ORGANIC ELECTRONIC DEVICES COMPRISING A LAYER COMPRISING AT LEAST ONE METAL ORGANIC COMPOUND AND AT LEAST ONE METAL OXIDE BASF SE (DE) 2011-12-22 US disclosed
WO-2011157779-A1 ORGANIC ELECTRONIC DEVICES COMPRISING A LAYER OF A PYRIDINE COMPOUND AND A 8-HYDROXYQUINOLINOLATO EARTH ALKALINE METAL, OR ALKALI METAL COMPLEX BASF SE (DE) 2011-12-22 WO disclosed
US-20110266528-A1 SUBSTITUTED CARBAZOLE DERIVATIVES AND USE THEREOF IN ORGANIC ELECTRONICS BASF SE (DE) 2011-11-03 US disclosed
WO-2011125020-A1 SUBSTITUTED CARBAZOLE DERIVATIVES AND USE THEREOF IN ORGANIC ELECTRONICS BASF SE (DE) 2011-10-13 WO disclosed
US-20110198578-A1 SILOLES SUBSTITUTED BY FUSED RING SYSTEMS AND USE THEREOF IN ORGANIC ELECTRONICS OSRAM OPTO SEMICONDUCTORS GMBH (DE) 2011-08-18 US disclosed
US-20110089408-A1 Organic Electronic Device and Dopant for Doping an Organic Semiconducting Matrix Material OSRAM OLED GMBH (DE) 2011-04-21 US disclosed
US-20110006288-A1 ORGANIC LUMINESCENT DEVICE AND MANUFACTURING METHOD THEREOF DENSO CORPORATION 2011-01-13 US disclosed
WO-2010097433-A1 QUINONE COMPOUNDS AS DOPANTS IN ORGANIC ELECTRONICS BASF SE (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110198578-A1 SILOLES SUBSTITUTED BY FUSED RING SYSTEMS AND USE THEREOF IN ORGANIC ELECTRONICS HLCS, LAGE3, SUMO3 CYP3A4 210/4885ALDH1A1 1138/4885L3MBTL1 2675/4885
US-12538704-B2 4H-imidazo[1,2-a]imidazoles for electronic applications RIF1, NR2E1, NR3C1 CYP3A4 720/4885ALDH1A1 680/4885L3MBTL1 2761/4885
US-20110089408-A1 Organic Electronic Device and Dopant for Doping an Organic Semiconducting Matrix Material AOC1, AOC2, AOC3 CYP3A4 2268/4885ALDH1A1 178/4885L3MBTL1 1534/4885
US-20110266528-A1 SUBSTITUTED CARBAZOLE DERIVATIVES AND USE THEREOF IN ORGANIC ELECTRONICS NR2E3, CHRNA5, CHRNA4 CYP3A4 256/4885ALDH1A1 2923/4885L3MBTL1 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.